Navigation Links
Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
Date:9/22/2008

Phase III Study to Explore the Effects of Oral Calcitonin, a combination of Salmon Calcitonin and Eligen Delivery Technology on Knee Osteoarthritis Treatment

CEDAR KNOLLS, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG and Nordic Bioscience have completed recruitment for a multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Eligen Technology to treat patients with osteoarthritis of the knee. This study, which will be used to support the filing with health authorities worldwide, includes more than 1,100 patients between 51 and 80 years old with a medical history and symptoms of knee osteoarthritis. The study will be conducted mainly in Europe and is estimated to complete second half 2010.

Osteoarthritis ("OA") is a clinical syndrome in which low-grade inflammation results in joint pain, caused by a wearing-away of cartilage that cushions the joints and the destruction or decrease of synovial fluid that lubricates those joints. As OA progresses, pain can result when the patient bears weight upon the joints, including walking and standing. OA is the most common form of arthritis, and affects nearly 21 million people in the United States, accounting for 25% of visits to primary care physicians, and half of all non-steroidal anti-inflammatory drug prescriptions. It is estimated that 80% of the population will have radiographic evidence of OA by age 65.

"The problems associated with osteoarthritis will escalate as the population ages," said Michael V. Novinski, President and Chief Executive Officer of Emisphere. "This Phase III study aims at demonstrating that oral salmon calcitonin, in combination with our Eligen drug delivery technology, may contribute to solving this problem, and also shows that Emisphere is a valuable partner in drug development."

About Emisphere Technologies, Inc.

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The website is: http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 13, 2008 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed on August 11, 2008.


'/>"/>
SOURCE Emisphere Technologies, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
3. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
4. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
5. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
6. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
7. Emisphere to Host Business Strategy Conference Call on February 7
8. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
9. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
10. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are looking ... Drug Association (PDA), the New York Interphex Show will open on March 21 and ... 625 exhibitors, the educational and networking opportunities are extremely valuable. INTERPHEX is viewed as ...
(Date:3/20/2017)... New York City, NY (PRWEB) , ... March ... ... pressure vessels and equipment for pharmaceutical and biotech companies, recently announced it will ... Javits Center in New York City. The intelliVessel is controlled by a touch ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... sample preparation methods in order to reduce the impact on instrumentation. ICP-MS is ... area of elemental analysis. , This presentation will discuss the pros and ...
(Date:3/20/2017)... ... March 20, 2017 , ... The fourth annual ... innovating to make an extraordinary impact on peoples’ lives, launches today. Sponsored by ... every 5 weeks and awards thousands in cash prizes to engineers, inventors and tinkerers ...
Breaking Biology Technology:
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:3/1/2017)... -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics ... has resigned, effective March 3, 2017, as co-Chief ... Treasurer of Aware citing a desire to retire.  Mr. ... the Board of Directors of Aware. ... co-President, General Counsel has been named Chief Executive Officer, ...
Breaking Biology News(10 mins):